Eli Lilly’s Trulicity’s Broad CV Label Spotlights GLP-1 Rivalry

Direct Impact On Novo Nordisk’s Ozempic ‘Limited’

 
• By Sten Stovall
  
Generate a summary of this article
Listen to this article
Beta

Trulicity’s broad CV label awarded by the US FDA should aid overall uptake of the GLP-1 class, cushioning the direct impact on Novo Nordisk’s rival, Ozempic, analysts said.

Doctor_Heart
Trulicity is first type 2 diabetes drug approved to cut CV events in adults with and without heart disease. • Source: Shutterstock

Product competition has sharpened between Eli Lilly & Co. and Novo Nordisk AS after the US Food and Drug Administration awarded the former’s blockbuster GLP-1 agonist Trulicity (dulaglutide) a cardiovascular (CV) label claim for diabetes patients with and without established heart disease. This makes it the first and only type 2 diabetes drug approved to reduce heart related risks in adults with and without established cardiovascular disease.

The distinction is unwelcome news for Denmark’s Novo Nordisk, whose competing GLP-1 Ozempic (injectable semaglutide) has a CV label only...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.